{"id":"placebo-to-raltegravir","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Elevated creatine kinase"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Raltegravir inhibits HIV integrase, an enzyme essential for viral replication. By blocking integrase activity, the drug prevents integration of viral DNA into the human genome, thereby halting HIV replication and reducing viral load. This mechanism is distinct from reverse transcriptase or protease inhibitors and represents the integrase inhibitor class of antiretrovirals.","oneSentence":"Raltegravir is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into the host cell's DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:46.027Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced adults"},{"name":"HIV-1 infection in pediatric patients"}]},"trialDetails":[{"nctId":"NCT03029689","phase":"PHASE3","title":"Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2017-07-28","conditions":"HIV","enrollment":61},{"nctId":"NCT03954327","phase":"PHASE2","title":"Combination Antiretroviral Therapy (cART) for PBC","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2021-03-01","conditions":"Primary Biliary Cholangitis","enrollment":37},{"nctId":"NCT00515827","phase":"PHASE2","title":"Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-11","conditions":"HIV Infections","enrollment":53},{"nctId":"NCT03060447","phase":"PHASE1","title":"Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-05-09","conditions":"HIV-1 Infection","enrollment":25},{"nctId":"NCT00631449","phase":"PHASE4","title":"Raltegravir Intensification in HIV-infected Patients","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-02","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02858401","phase":"PHASE1","title":"Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-29","conditions":"HIV-1 Infection","enrollment":48},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT02131233","phase":"PHASE3","title":"Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-23","conditions":"HIV Infection","enrollment":802},{"nctId":"NCT00843713","phase":"PHASE4","title":"Effect of Raltegravir on Endothelial Function in HIV-Infected Patients","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-01","conditions":"HIV Infection, Inflammation, Cardiovascular Disease","enrollment":56},{"nctId":"NCT01227824","phase":"PHASE3","title":"A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-10-19","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":828},{"nctId":"NCT01568892","phase":"PHASE3","title":"Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2012-04-18","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT01199731","phase":"PHASE2","title":"Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2010-10-05","conditions":"Infection, Human Immunodeficiency Virus","enrollment":30},{"nctId":"NCT00443703","phase":"PHASE3","title":"MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-05","conditions":"HIV Infection","enrollment":352},{"nctId":"NCT00369941","phase":"PHASE3","title":"A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-08","conditions":"HIV Infections","enrollment":566},{"nctId":"NCT00443729","phase":"PHASE3","title":"MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-05","conditions":"HIV Infection","enrollment":355},{"nctId":"NCT00745823","phase":"PHASE3","title":"A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09","conditions":"HIV","enrollment":775},{"nctId":"NCT00293254","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-02","conditions":"HIV Infections","enrollment":351},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT01154673","phase":"PHASE2, PHASE3","title":"Effects of Intensive cART During Acute/Early HIV Infection","status":"COMPLETED","sponsor":"University of Toronto","startDate":"2011-11","conditions":"Acute HIV Infection","enrollment":32},{"nctId":"NCT00105157","phase":"PHASE2","title":"Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"HIV Infections, Acquired Immunodeficiency Syndrome","enrollment":179},{"nctId":"NCT00100048","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-01","conditions":"HIV Infections, Acquired Immunodeficiency Syndrome","enrollment":206},{"nctId":"NCT00293267","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-02","conditions":"HIV Infections","enrollment":352},{"nctId":"NCT00562510","phase":"PHASE3","title":"Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery","status":"TERMINATED","sponsor":"Pedro Cahn","startDate":"2008-08","conditions":"HIV Infections","enrollment":20},{"nctId":"NCT00772590","phase":"PHASE4","title":"Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2009-03","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT00797381","phase":"","title":"Efficacy and Safety of MK-0518 in Treatment-Experienced HIV-1 Infected Adult Patients With Hemophilia","status":"UNKNOWN","sponsor":"Shanghai Public Health Clinical Center","startDate":"2009-05","conditions":"HIV Infection, Hemophilia A","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":50,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to Raltegravir","genericName":"Placebo to Raltegravir","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Raltegravir is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into the host cell's DNA. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in pediatric patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}